Abstract
The development of a novel tumor-targeting photosensitizer delivery system, with potential ability to selectively transport the photosensitizer prodrug 5-aminolevulinic acid methyl ester (MAL) into the tumor site has been herein described. Conjugation of MAL to folic acid (FA) via an unnatural β-peptide linker has been carried out almost entirely by an efficient solid phase approach. This molecular system has been devised for possible applications in selective photodynamic diagnosis (PDD) and therapy (PDT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
